Table of Content

1. Executive Summary
   1.1. India CDMO Market Snapshot, 2024 and 2031
   1.2. Market Opportunity Assessment, 2024 - 2031, US$ Mn
   1.3. Key Market Trends
   1.4. Future Market Projections
   1.5. Premium Market Insights
   1.6. Industry Developments and Key Market Events
   1.7. PMR Analysis and Recommendations
2. Market Overview
   2.1. Market Scope and Definition
   2.2. Market Dynamics
       2.2.1. Drivers
       2.2.2. Restraints
       2.2.3. Opportunity
       2.2.4. Challenges
       2.2.5. Key Trends
   2.3. Macro-Economic Factors
       2.3.1. Global Sectorial Outlook
       2.3.2. Global GDP Growth Outlook
       2.3.3. Global Healthcare Spending Outlook
   2.4. COVID-19 Impact Analysis
   2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
   3.1. Regulatory Landscape
   3.2. Service Adoption Analysis
   3.3. Value Chain Analysis
   3.4. Key Deals and Mergers
   3.5. PESTLE Analysis
   3.6. Porter’s Five Force Analysis
4. India CDMO Market Outlook: Historical (2018 - 2023) and Forecast (2024 - 2031)
   4.1. Key Highlights
       4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
       4.1.2. Absolute $ Opportunity
   4.2. Market Size (US$ Mn) Analysis and Forecast
       4.2.1. Historical Market Size (US$ Mn) Analysis, 2018-2022
       4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2023-2031
   4.3. India CDMO Market Outlook: Service Type
       4.3.1. Introduction / Key Findings
       4.3.2. Historical Market Size (US$ Mn) Analysis, By Service Type, 2018 - 2022
       4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Service Type, 2023 - 2031
           4.3.3.1. Contract Development Services
           4.3.3.2. Preclinical Development
           4.3.3.3. Clinical Development
           4.3.3.4. Analytical and Bioanalytical Services
           4.3.3.5. Contract Manufacturing Services
           4.3.3.6. Active Pharmaceutical Ingredients (APIs) Manufacturing
           4.3.3.7. Finished Dosage Forms (FDFs) Manufacturing
           4.3.3.8. Biologics Manufacturing
           4.3.3.9. Packaging
   4.4. Market Attractiveness Analysis: Service Type
   4.5. India CDMO Market Outlook: Product Type
       4.5.1. Introduction / Key Findings
       4.5.2. Historical Market Size (US$ Mn) Analysis, By Product Type, 2018 - 2022
       4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product Type, 2023 - 2031
           4.5.3.1. Small Molecules
           4.5.3.2. Biologics
           4.5.3.3. Biosimilars
           4.5.3.4. Vaccines
           4.5.3.5. Others
   4.6. Market Attractiveness Analysis: Product Type
   4.7. India CDMO Market Outlook: Scale of Operation
       4.7.1. Introduction / Key Findings
       4.7.2. Historical Market Size (US$ Mn) Analysis, By Scale of Operation, 2018 - 2022
       4.7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Scale of Operation, 2023 - 2031
           4.7.3.1. Commercial Scale
           4.7.3.2. Clinical Scale
   4.8. Market Attractiveness Analysis: Scale of Operation
   4.9. India CDMO Market Outlook: Therapeutic Area
       4.9.1. Introduction / Key Findings
       4.9.2. Historical Market Size (US$ Mn) Analysis, By Therapeutic Area, 2018 - 2022
       4.9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Therapeutic Area, 2023 - 2031
           4.9.3.1. Oncology
           4.9.3.2. Cardiovascular Diseases
           4.9.3.3. Infectious Diseases
           4.9.3.4. Central Nervous System (CNS) Disorders
           4.9.3.5. Others
   4.10. Market Attractiveness Analysis: Therapeutic Area
5. Competition Landscape
   5.1. Market Share Analysis, 2023
   5.2. Market Structure
       5.2.1. Competition Intensity Mapping By Market
       5.2.2. Competition Dashboard
   5.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
       5.3.1. Piramal Pharma Solutions
           5.3.1.1. Overview
           5.3.1.2. Segments and Products
           5.3.1.3. Key Financials
           5.3.1.4. Market Developments
           5.3.1.5. Market Strategy
       5.3.2. Syngene International
       5.3.3. Dr. Reddy’s Laboratories
       5.3.4. Divi’s Laboratories
       5.3.5. Lupin Limited
       5.3.6. Sun Pharmaceutical Industries Ltd.
       5.3.7. Aurobindo Pharma
       5.3.8. Jubilant Pharmova (Jubilant Biosys & Jubilant Generics)
       5.3.9. Glenmark Pharmaceuticals
       5.3.10. Capsule Pharma
       5.3.11. Laurus Labs
       5.3.12. Strides Pharma Science
       5.3.13. Aurigene Pharmaceutical
6. Appendix
   6.1. Research Methodology
   6.2. Research Assumptions
   6.3. Acronyms and Abbreviations